EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

The PCOS ‐to‐ PMOS shift in the broader history of nomenclature changes and its uncertain impact on clinical practice

Elina Aleksejeva‐Zagura, Piotr Laudański, Ganesh Acharya, Andres Salumets

Acta Obstetricia et Gynecologica Scandinavica · 2026-10-29

DOI: 10.1111/aogs.70380 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Proposed renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) aims to broaden multidisciplinary care. However, it may obscure reproductive manifestations and introduce phenotypic ascertainment bias. Historical examples of nomenclature changes suggest that clinical benefits depend heavily on diagnostic, therapeutic, and etiological advances and education. Although formal cost‐effectiveness analysis of nomenclature changes are lacking, our preliminary estimates suggest that implementation may entail substantial cost and healthcare resource requirements, while its clinical benefits remain uncertain.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →